SmartTRAK Life Sciences News and Analysis Blog in the Orthopedics, Wound, and Neuro Therapies Market Segments
.png)
SmartTRAK interviews Suneet Varma, CEO of INTENT Biologics, to discuss the company’s novel exosome techn...
SmartTRAK spoke with the Westbrook Weaver, CEO of Tempo Therapeutics, to discuss the company’s new techn...
Wound GM Kris Flinn and Senior Analysts Elizabeth Anderson and Jay Merkel discuss the impact of the fina...
Wound GM Kris Flinn and Senior Analysts Elizabeth Anderson and Jay Merkel discuss the impact of the fina...
It is with both gratitude and admiration that we announce the retirement of Susan Paquette, our former V...
SmartTRAK reports from Boston, where discussions about the future of wound care were distracted by signi...
SmartTRAK reviews possible alternatives to LCDs and CMS’ proposed payment model for Cellular, Acellular,...
James Voos, MD, chair of the Department of Orthopedics and Sports Medicine at University Hospitals Cleve...
SmartTRAK's industry experts discuss CMS’ proposed changes to skin substitutes reimbursement and their p...
SmartTRAK reviews CMS’ new WISeR model and its potential impact on the US Skin Substitutes Market. A new...
Login